Citrini, the publisher of the "AI Apocalypse Report," asked Claude to study scorpion venom with the aim of finding new investment opportunities Beating AI News: In February of this year, Citrini Research released "2028 Global Intelligence Crisis", envisioning AI replacing white-collar workers on a large scale and triggering an economic recession, which once stirred up Wall Street. Recently, this investment research institution has collaborated with Anthropic to have Claude try designing anti scorpion venom proteins. Citrini has been seeking investment opportunities outside of AI infrastructure since June this year, focusing on the long-term sluggish life sciences sector. But experts are highly divided on the prospects of AI pharmaceuticals, and five researchers lacking drug development experience have decided to personally verify it. They chose scorpion venom because its structure is relatively clear, making it easier to conduct experiments. Moreover, traditional anti toxin serum requires injecting toxins into horses and extracting antibodies, which is a cumbersome and costly production process. The team has obtained a research model from Anthropic that has not yet been made public. With the assistance of researchers, Claude spent 64 hours generating approximately 320000 protein designs and screening out 180 candidates. Subsequently, Claude supplemented 31 types and handed them over to two laboratories for testing. The final 17 proteins were able to bind to the target scorpion venom, but none of them simultaneously bind to multiple toxins, and their ability to truly detoxify has not been verified. What really interests Citrini is the follow-up experiments. AI completed the design in a few days, but laboratory validation took nearly two months. The computing power cost is approximately $50000, to be borne by Anthropic; The laboratory bill is close to $150000. Citrini thus discovered new investment opportunities. As AI accelerates drug design, more candidate molecules may need to be sent to the laboratory for synthesis, testing, and validation. These tasks cannot be completed solely by computers, and require expensive equipment, reagents, and professional personnel. Therefore, Citrini not only focuses on companies that use AI to develop drugs, but also has a positive outlook on Charles River, Revvity, and Tecan, which provide experimental outsourcing, testing equipment, and automation tools for pharmaceutical companies. [Original link]